首页> 外文OA文献 >Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

【2h】

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

机译：矫正：Fedaxomicin用于治疗炎症性肠病患者的患者危险患者，令人兴奋的CDI，肾损伤或肝损伤：常规临床用途的回顾性研究（海葵）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Maria J. G. T. Vehreschild; Surabhi Taori; Simon D. Goldenberg; Florian Thalhammer; Emilio Bouza; Joop van Oene; Graham Wetherill; Areti Georgopali;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (vol 37, pg 2097, 2018) [J] . Vehreschild Maria J. G. T., Taori Surabhi, Goldenberg Simon D., European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology . 2019,第1期

机译：矫正：Fedaxomicin用于治疗患有炎症性肠病患者的患者腹股沟困难感染（CDI），令人兴奋的CDI，肾脏损伤或肝损伤：常规临床用途的回顾性研究（白莲奈）（Vol 37，PG 2097， 2018）
2. Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) [J] . Vehreschild Maria J. G. T., Taori Surabhi, Goldenberg Simon D., European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology . 2018,第11期

机译：Fidaxomicin用于治疗患有炎症性肠病患者的患者腹股沟困难感染（CDI），令人兴奋的CDI，肾损伤或肝损伤：常规临床用途的回顾性研究（海葵）
3. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain [J] . Rubio-Terres C., Cobo Reinoso J., Grau Cerrato S., European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology . 2015,第11期

机译：非达索霉素在西班牙特殊人群（患有癌症，伴随抗生素治疗或肾功能不全的患者）治疗艰难梭菌感染的经济评估
4. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease fulminant CDI renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) [O] . Maria J. G. T. Vehreschild, Surabhi Taori, Simon D. Goldenberg, -1

机译：校正至：非达霉素治疗炎症性肠病暴发性CDI肾功能不全或肝功能不全的高危患者的艰难梭菌感染（CDI）：常规临床应用的回顾性研究（ANEMONE）
5. PIN60 Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also Known as Clostridium Difficile-Associated Diarrhoea (CDAD) in Spain [O] . Cobo Reinoso J., Grau Cerrato S., Mensa Pueyo J., 2014

机译：非达索霉素用于治疗艰难梭菌感染（CDI）的PIN60经济评估在西班牙也称为艰难梭菌相关性腹泻（CDAD）

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

著录项

相似文献

相关主题

期刊订阅